The correlations of the cytogenetic responses and the molecular responses during imatinib therapy for chronic myelogenous leukemia

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001697

Enrollment

Unknown

Registered

2011-11-08

Start date

2006-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia

Interventions

one:imatinib

Eligibility

Sex/Gender

All

Age

10 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with Ph chromosome positive chronic myelogenous leukemia who received imatinib therapy

Exclusion criteria

Exclusion criteria: Patients with Ph chromosome negative chronic myelogenous leukemia

Design outcomes

Primary

Measure	Time frame
Cytogenetic response (Ph positive cell %) in bone;Molecular response (the level of bcr-abl transcripts) in bone marrow;Molecular response (the level of bcr-abl transcripts) in peripheral blood;	—

Countries

China

Contacts

Public ContactXiaojun Huang

xjhrm@medmail.com.cn+86 10 88326005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026